G3BP2 and neoplasm: More in vivo studies are required to evaluate the potential combinatory effect of rhMG53 and cisplatin to determine their ability to inhibit tumor growth of drug-resistant NSCLCs, or other aggressive cancers with abnormal function of G3BP2/SG.